Tetraphase Pharmaceuticals, Inc. (TTPH) Shares Sold by California State Teachers Retirement System

California State Teachers Retirement System lowered its stake in shares of Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) by 6.4% during the 2nd quarter, according to its most recent filing with the SEC. The firm owned 67,020 shares of the biopharmaceutical company’s stock after selling 4,600 shares during the period. California State Teachers Retirement System owned approximately 0.13% of Tetraphase Pharmaceuticals worth $478,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently bought and sold shares of the company. UBS Group AG lifted its stake in shares of Tetraphase Pharmaceuticals by 2.3% in the 1st quarter. UBS Group AG now owns 17,269 shares of the biopharmaceutical company’s stock worth $159,000 after purchasing an additional 387 shares during the period. Schwab Charles Investment Management Inc. lifted its stake in shares of Tetraphase Pharmaceuticals by 0.7% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 129,681 shares of the biopharmaceutical company’s stock worth $925,000 after purchasing an additional 874 shares during the period. Rhumbline Advisers lifted its stake in shares of Tetraphase Pharmaceuticals by 5.7% in the 2nd quarter. Rhumbline Advisers now owns 51,633 shares of the biopharmaceutical company’s stock worth $368,000 after purchasing an additional 2,780 shares during the period. Voya Investment Management LLC lifted its stake in shares of Tetraphase Pharmaceuticals by 17.8% in the 2nd quarter. Voya Investment Management LLC now owns 20,583 shares of the biopharmaceutical company’s stock worth $147,000 after purchasing an additional 3,104 shares during the period. Finally, Alliancebernstein L.P. lifted its stake in shares of Tetraphase Pharmaceuticals by 6.9% in the 2nd quarter. Alliancebernstein L.P. now owns 59,200 shares of the biopharmaceutical company’s stock worth $422,000 after purchasing an additional 3,800 shares during the period. Institutional investors and hedge funds own 58.19% of the company’s stock.

Several equities analysts have recently weighed in on the stock. Needham & Company LLC reiterated a “hold” rating on shares of Tetraphase Pharmaceuticals in a research note on Sunday, September 17th. Zacks Investment Research upgraded shares of Tetraphase Pharmaceuticals from a “hold” rating to a “buy” rating and set a $7.75 price objective on the stock in a research note on Saturday, September 23rd. HC Wainwright reiterated a “buy” rating and issued a $17.00 price objective on shares of Tetraphase Pharmaceuticals in a research note on Tuesday. BidaskClub cut shares of Tetraphase Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday, August 10th. Finally, Stifel Nicolaus reiterated a “buy” rating and issued a $13.00 price objective on shares of Tetraphase Pharmaceuticals in a research note on Tuesday, September 12th. Two investment analysts have rated the stock with a sell rating, two have given a hold rating and four have assigned a buy rating to the company’s stock. Tetraphase Pharmaceuticals presently has an average rating of “Hold” and a consensus target price of $15.15.

In related news, insider Jacques Dumas sold 8,750 shares of the stock in a transaction that occurred on Tuesday, October 31st. The shares were sold at an average price of $6.03, for a total value of $52,762.50. Following the completion of the sale, the insider now directly owns 8,750 shares of the company’s stock, valued at approximately $52,762.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director L Patrick Gage bought 3,880 shares of Tetraphase Pharmaceuticals stock in a transaction that occurred on Wednesday, November 29th. The stock was purchased at an average cost of $6.45 per share, with a total value of $25,026.00. Following the completion of the acquisition, the director now directly owns 38,880 shares in the company, valued at approximately $250,776. The disclosure for this purchase can be found here. Corporate insiders own 5.50% of the company’s stock.

Shares of Tetraphase Pharmaceuticals, Inc. (NASDAQ TTPH) opened at $5.84 on Friday. Tetraphase Pharmaceuticals, Inc. has a fifty-two week low of $3.57 and a fifty-two week high of $9.93.

Tetraphase Pharmaceuticals (NASDAQ:TTPH) last released its earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($0.63) earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.63). The company had revenue of $4.10 million during the quarter, compared to analyst estimates of $1.59 million. Tetraphase Pharmaceuticals had a negative net margin of 1,382.33% and a negative return on equity of 88.27%. The firm’s quarterly revenue was up 355.6% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.58) EPS. research analysts anticipate that Tetraphase Pharmaceuticals, Inc. will post -2.88 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This article was first posted by Transcript Daily and is the sole property of of Transcript Daily. If you are viewing this article on another publication, it was stolen and reposted in violation of US and international copyright law. The original version of this article can be viewed at https://transcriptdaily.com/2017/12/08/tetraphase-pharmaceuticals-inc-ttph-shares-sold-by-california-state-teachers-retirement-system.html.

Tetraphase Pharmaceuticals Profile

Tetraphase Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant gram-negative infections.

Institutional Ownership by Quarter for Tetraphase Pharmaceuticals (NASDAQ:TTPH)

Receive News & Ratings for Tetraphase Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply